Boundless Bio gets FDA clearance for cancer drug trial Jan 20, 2026 07:01AM
Boundless Bio (BOLD) Halted, News Pending Jan 20, 2026 06:55AM
Audentes Therapeutics (BOLD) Tops Q3 EPS by 47c Nov 5, 2025 04:20PM
H.C. Wainwright Reiterates Buy Rating on Boundless Bio Inc. (BOLD) Oct 24, 2025 06:52AM
Boundless Bio Inc. (BOLD) PT Lowered to $4 at H.C. Wainwright Aug 11, 2025 06:40AM


Aug 5, 2025 09:08AM Audentes Therapeutics (BOLD) Tops Q2 EPS by 32c
Jun 2, 2025 06:36AM H.C. Wainwright Assumes Boundless Bio Inc. (BOLD) at Buy
May 28, 2025 05:45AM Leerink Partners Downgrades Boundless Bio Inc. (BOLD) to Market Perform
May 9, 2025 04:46PM Audentes Therapeutics (BOLD) Tops Q1 EPS by 173c
Apr 1, 2025 04:05PM Boundless Bio (BOLD) Files $400M Mixed Shelf
Feb 3, 2025 10:00AM Boundless Bio (BOLD) Appoints Robert Doebele as Chief Medical Officer
Dec 13, 2024 06:17AM Guggenheim Downgrades Boundless Bio Inc. (BOLD) to Neutral
Dec 12, 2024 04:02PM Boundless Bio (BOLD) Announces Pipeline and Leadership Updates
Nov 8, 2024 04:19PM Audentes Therapeutics (BOLD) Misses Q3 EPS by 1c
Oct 14, 2024 08:00AM Boundless Bio (BOLD) Announces CFO Departure
Aug 12, 2024 04:03PM Boundless Bio (BOLD) Provides Business Updates Focused on Key Value Drivers and Reports Second Quarter 2024 Financial Results